Csaba P Kovesdy
Overview
Explore the profile of Csaba P Kovesdy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
594
Citations
18862
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kovesdy C
Clin J Am Soc Nephrol
. 2025 Mar;
PMID: 40085173
Obesity is a worldwide epidemic with a future projected growth of 40% over ten years. Obesity increases the risk of diabetes, hypertension and cardiovascular disease, and it also leads to...
2.
Kovesdy C, Ebert N, Vizcaya D, Walsh M, Kosiborod M, Layton J, et al.
Nephron
. 2025 Feb;
:1-26.
PMID: 40015260
Introduction: In 2021, finerenone - a novel, selective non-steroidal mineralocorticoid receptor antagonist - was approved in the US to treat adults with CKD and T2D This study aimed to describe...
3.
Chao C, Kovesdy C, Merchant R
Kidney Res Clin Pract
. 2025 Feb;
PMID: 39973319
Population aging is a global challenge that increases the burden of chronic kidney disease (CKD) and geriatric syndromes such as sarcopenia, sarcopenic obesity, and frailty. These conditions affect almost half...
4.
Takahashi R, Bui T, Elali I, Tran D, Sumida K, Thomas F, et al.
Am J Nephrol
. 2025 Jan;
:1-11.
PMID: 39870055
Introduction: Niacin is a non-statin lipid-lowering therapy that has been shown to lower triglycerides and improve other risk factors for renal outcomes. Despite these favorable data, the effect of niacin...
5.
Mukhopadhyay A, Haque Mondol M, Rahman M, Unicomb L, Khan R, Mazumder H, et al.
Environ Int
. 2024 Dec;
195:109208.
PMID: 39705978
High ambient heat can directly influence blood pressure (BP) through the vasodilation of the skin vasculature and indirectly by affecting urinary volume and electrolyte levels. We evaluated the direct and...
6.
Johannes C, Ziemiecki R, Pladevall-Vila M, Ebert N, Kovesdy C, Thomsen R, et al.
Diabetes Ther
. 2024 Dec;
16(2):205-226.
PMID: 39688776
Introduction: The clinical landscape for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) is rapidly evolving. As part of the FOUNTAIN platform (NCT05526157; EUPAS48148),...
7.
Rhee C, Gianchandani R, Kerr D, Philis-Tsimikas A, Kovesdy C, Stanton R, et al.
J Diabetes Sci Technol
. 2024 Nov;
19(1):217-245.
PMID: 39611379
This report represents the conclusions of 15 experts in nephrology and endocrinology, based on their knowledge of key studies and evidence in the field, on the role of continuous glucose...
8.
Rhee C, Kovesdy C, Unruh M, Crowley S, Geller D, Goldfarb D, et al.
Curr Opin Nephrol Hypertens
. 2024 Nov;
34(1):33-40.
PMID: 39611277
Purpose Of Review: Initiation of hemodialysis treatment with a thrice-weekly prescription is currently the standard of care irrespective of patients' residual kidney function (RKF), comorbidities, and preferences. Recent Findings: Each...
9.
Sato A, Rodriguez-Molina D, Yoshikawa-Ryan K, Yamashita S, Okami S, Liu F, et al.
J Clin Med
. 2024 Sep;
13(17).
PMID: 39274317
In the phase 3 clinical trials FIGARO-DKD and FIDELIO-DKD, finerenone reduced the risk of cardiovascular and kidney events among people with chronic kidney disease (CKD) and type 2 diabetes (T2D)....
10.